Lenzilumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Lenzilumab
Monoclonal antibody
Type Whole antibody
Source Human
Target human colony stimulating factor 2
Clinical data
Synonyms KB003
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C6474H10024N1748O2010S42
Molar mass 145.85 kDa

Lenzilumab (INN) (alternative identifier KB003)[1] is a humanized monoclonal antibody (class IgG1 kappa)[2] that targets colony stimulating factor 2 (CSF2)/granulocyte-macrophage colony stimulating factor (GM-CSF) designed for the treatment of chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML).[3][4][5] In vitro studies on human cells have demonstrated that Lenzilumab can induce sensitivity in myeloid and monocytic cells suggesting the antibody's applicability in CMML and JMML indications.[6]

This drug is under development by KaloBios Pharmaceuticals Inc. and as of 2017 is currently undergoing clinical trials for CMML.[7][8] Prior to application in treating CMML, Lenzilumab was assessed for use in treating inadequately controlled asthma[9] and rheumatoid arthritis.[10]

References[edit]

  1. ^ "Lenzilumab - AdisInsight". adisinsight.springer.com. Retrieved 2017-03-24. 
  2. ^ "Anti-Human CSF2 Therapeutic Antibody (lenzilumab) - Creative Biolabs". www.creativebiolabs.net. Retrieved 2017-03-24. 
  3. ^ "Lenzilumab :: KaloBios Pharmaceuticals, Inc. (KBIO)". KaloBios Pharmaceuticals, Inc. Retrieved 2017-03-24. 
  4. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lenzilumab, American Medical Association.
  5. ^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2). 
  6. ^ Padron, Eric; Painter, Jeffrey S.; Kunigal, Sateesh; Mailloux, Adam W.; McGraw, Kathy; McDaniel, Jessica M.; Kim, Eunhee; Bebbington, Christopher; Baer, Mark (2013-06-20). "GM-CSF–dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia". Blood. 121 (25): 5068–5077. doi:10.1182/blood-2012-10-460170. ISSN 0006-4971. PMC 4347259Freely accessible. PMID 23632888. 
  7. ^ Inc., KaloBios Pharmaceuticals. "KaloBios Announces First Patient Dosed in Phase 1 Study of Lenzilumab for the Treatment of Chronic Myelomonocytic Leukemia". GlobeNewswire News Room. Retrieved 2017-03-24. 
  8. ^ "Study of Lenzilumab (KB003) in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML) - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2017-03-24. 
  9. ^ "Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2017-03-24. 
  10. ^ "Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2017-03-24.